Table 1 Patient characteristics at the time of mepolizumab treatment start

Age—median (IQR)

61.8 (55.0–72.0)

Female—n (%)

4 (36.3)

HES duration (y)—mean ± SD

7.27 ± 6.38

Baseline HES therapy—n (%)

 Prednisone < 10 mg/day

5 (45)

 Prednisone ≥ 10 mg/day

6 (55)

 Prednisone dose (mg), median (IQR)

10.0 (7.5–12.5)

 Baseline blood eosinophil count (cells/μL)—median (IQR)

1000 (870–2100)

HES manifestations—n (%)

 Constitutional (fever, fatigue, weight loss)

8 (72)

 Respiratory (dyspnoea, cough, lung infiltrates)

7 (63)

 Musculoskeletal (muscle or joint pain)

4 (36)

 Neurologic (paraesthesia, hypoesthesia)

5 (45)

 Skin (dermatitis, urticaria)

4 (36)

 Gastrointestinal (Abdominal pain or bloating, vomiting, diarrhoea)

4 (36)